2016 Hematological Malignancies

HD10: Long-term outcome

10 year estimate [95%-CI] Hazard Ratio [95%-CI]

10 year estimate [95%-CI] Hazard Ratio [95%-CI]

4ABVD+30Gy 2ABVD+20Gy

87.4% [82.9% to 91.9%] 87.2% [82.9% to 91.5%]

4ABVD+30Gy 2ABVD+20Gy

93.6% [90.5% to 96.7%] 94.1% [91.1% to 97.1%]

1.0 [0.6 to 1.5]

0.9 [0.5 to 1.6]

Difference -0.2% [-6.4% to 6.0%] Median observation time 98 months

Difference 0.5% [-3.8% to 4.9%] Median observation time 113 months

286

293

298

298

 No difference in 10-year PFS and OS between most and least intensive arms of therapy (i.e. 4 vs. 2xABVD and 20 vs. 30Gy IF-RT)